Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating...
“ Assembly Bio common stock expected to begin trading on a split-adjusted basis on February 12, 2024 “ SOUTH SAN FRANCISCO, Calif., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc....
Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D virusesInitial clinical data...
Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio
Assembly Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
#NAME?
Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyondNow anticipate four development candidates from expanded pipeline in clinical...
FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today announced that the companies have entered into a 12-year partnership to advance the research and development of novel antiviral therapies, with an initial focus in Assembly Bio’s established areas of herpesviruses, hepatitis B virus (HBV) and hepatitis D virus (HDV).
-- One poster and one oral presentation selected, with the poster highlighting new preclinical data from the Company™s interferon-α receptor agonist program -- SOUTH SAN FRANCISCO, Oct. 11, 2023 ...
ˆ’ ABI-6250 demonstrated low nanomolar potency against hepatitis D virus and selective inhibition of NTCP in preclinical studies with once-daily dosing projected ˆ’ Progression into clinical studies...